Cubist Seeks Calixa In Antibiotic Push | December 21, 2009 Issue - Vol. 87 Issue 51 | Chemical & Engineering News
Volume 87 Issue 51 | p. 23 | Concentrates
Issue Date: December 21, 2009

Cubist Seeks Calixa In Antibiotic Push

Department: Business
Keywords: Cubist Pharmaceuticals, Calixa Therapeutics

Cubist Pharmaceuticals has agreed to acquire privately held Calixa Therapeutics for $92.5 million in cash plus potential payments of up to $310 million, depending on the performance of CXA-201, Calixa’s lead compound. CXA-201 is a combination of CXA-101 and the β-lactamase inhibitor tazobactam. CXA-101 is a novel cephalosporin antibiotic now in Phase II trials. Both CXA-201 and CXA-101 are targeted at serious gram-negative infections. Cubist already markets daptomycin, the first in a new class of antibiotics called lipopeptides.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment